Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
NewAmsterdam Pharma announced dosing the first participant in SPINOZA, a Phase 2b trial testing obicetrapib in preclinical Alzheimer’s disease.Key Highlights:Original SEC Filing: NewAmsterdam Pharma Co N.V. [ NAMS ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Co…
SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-- The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additi…
NewAmsterdam Pharma dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in preclinical Alzheimer’s disease.